Fusion Pharmaceuticals (FUSN) shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca (AZN) under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion. Approximately 80.83% of the issued and outstanding shares were voted. The arrangement is subject to court approval, as well as other customary closing conditions. Subject to the satisfaction of such conditions, the transaction is expected to be completed in Q2.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FUSN:
- Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
- Fusion announces first patient dosed in Phase 2 portion of AlphaBreak trial
- Fusion Pharmaceuticals Inc. Grapples with Tax Uncertainty: Potential Impacts on Finances and Investor Trust
- Largest borrow rate increases among liquid names
- Fusion Pharmaceuticals Poised for AstraZeneca Acquisition
Questions or Comments about the article? Write to editor@tipranks.com